Histone Modifications

Migration, Crosslink

📖

Histone Modifications

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-histone-modifications

📖 Wiki Page

entity1662 wordssynced 2026-04-02

Introduction

Histone Modifications is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Histone modifications are post-translational chemical alterations to histone proteins that regulate chromatin structure and gene expression without changing the DNA sequence. These epigenetic modifications - including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation - control the accessibility of DNA to transcriptional machinery and play fundamental roles in neuronal gene expression, synaptic plasticity, and memory formation. In neurodegenerative diseases, widespread dysregulation of histone modifications contributes to aberrant gene expression programs that promote neuroinflammation, synaptic loss, and neuronal death ([Nativio et al., 2020](https://doi.org/10.1038/s41593-020-00719-w)). [@graff2012]

Histone deacetylase (HDAC inhibitors have emerged as promising therapeutic candidates for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/diseases/huntingtons), and [ALS](/diseases/amyotrophic-lateral-sclerosis), with several compounds advancing through preclinical and clinical development ([Shukla & Singh, 2024](https://pubmed.ncbi.nlm.nih.gov/38830501/)). [@shukla2024]

Histone Biology

Nucleosome Structure

...

Introduction

Histone Modifications is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Histone modifications are post-translational chemical alterations to histone proteins that regulate chromatin structure and gene expression without changing the DNA sequence. These epigenetic modifications - including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation - control the accessibility of DNA to transcriptional machinery and play fundamental roles in neuronal gene expression, synaptic plasticity, and memory formation. In neurodegenerative diseases, widespread dysregulation of histone modifications contributes to aberrant gene expression programs that promote neuroinflammation, synaptic loss, and neuronal death ([Nativio et al., 2020](https://doi.org/10.1038/s41593-020-00719-w)). [@graff2012]

Histone deacetylase (HDAC inhibitors have emerged as promising therapeutic candidates for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/diseases/huntingtons), and [ALS](/diseases/amyotrophic-lateral-sclerosis), with several compounds advancing through preclinical and clinical development ([Shukla & Singh, 2024](https://pubmed.ncbi.nlm.nih.gov/38830501/)). [@shukla2024]

Histone Biology

Nucleosome Structure

DNA in the nucleus is packaged around histone octamers to form nucleosomes, the fundamental units of chromatin: [@guan2009]

Core histones: Two copies each of H2A, H2B, H3, and H4 form the octamer
DNA wrapping: ~147 bp of DNA wraps ~1.65 turns around each octamer
Linker histone: H1 binds linker DNA between nucleosomes, compacting higher-order chromatin structure
Histone tails: N-terminal tails protrude from the nucleosome and are the primary targets for post-translational modifications

The Histone Code

The "histone code hypothesis" proposes that specific combinations of histone modifications create a code read by effector proteins to regulate gene expression: [@peleg2010]

Euchromatin (open, transcriptionally active): Associated with acetylation, H3K4me3, H3K36me3
Heterochromatin (closed, transcriptionally silent): Associated with deacetylation, H3K9me3, H3K27me3
Bivalent domains: Carry both activating (H3K4me3) and repressive (H3K27me3) marks; "poised" for rapid activation or silencing

Major Types of Histone Modifications

Acetylation

The most studied histone modification in neurodegeneration: [@konsoula2024]

Mechanism: [@zheng2022]

Addition of acetyl groups to lysine residues on histone tails
Writers: Histone acetyltransferases (HATs) - CBP/p300, PCAF, GCN5, Tip60
Erasers: Histone deacetylases (HDACs) - 18 mammalian HDACs in 4 classes
Readers: Bromodomain-containing proteins (BRD2, BRD4)

Effect: Neutralizes the positive charge on lysine, weakening histone-DNA interactions and opening chromatin for transcription. [@stilling2011]

Key acetylation marks in the brain: [@fischer2007]

| Mark | Location | Function | Change in AD | [@chuang2009]
|------|----------|----------|-------------| [@frost2014]
| H3K9ac | Promoters | Gene activation | Globally decreased | [@cook2014]
| H3K14ac | Promoters | Gene activation | Decreased |
| H3K27ac | Enhancers, promoters | Active enhancer mark | Redistributed |
| H4K16ac | Gene bodies | Transcription elongation | Decreased |
| H4K12ac | Promoters | Memory-related gene expression | Decreased with aging |

Methylation

Mechanism:

Addition of methyl groups to lysine or arginine residues
Writers: Histone methyltransferases (HMTs) - SET-domain proteins (EZH2, G9a, SUV39H1), DOT1L
Erasers: Histone demethylases (HDMs) - LSD1, JMJD family
Readers: Chromodomain, Tudor domain, PHD finger proteins
Can be mono-, di-, or trimethylated (each with distinct functions)

Key methylation marks:

H3K4me3: Activating mark at promoters; decreased at memory genes in AD
H3K9me2/3: Repressive mark; increased at neuroprotective genes in AD
H3K27me3: Polycomb-mediated silencing; altered in neurodegeneration
H3K36me3: Transcription elongation; mark of actively transcribed genes
H4K20me3: Constitutive heterochromatin; involved in DNA damage response

Phosphorylation

Addition of phosphate groups to serine, threonine, or tyrosine residues
H3S10ph: Associated with mitotic chromosome condensation and immediate-early gene activation
gamma-H2AX (H2AXS139ph): DNA double-strand break marker; increased in AD and ALS [neurons](/entities/neurons), indicating elevated DNA damage
Catalyzed by kinases (Aurora B, MSK1, ATM) and removed by phosphatases

Ubiquitination

H2AK119ub: Polycomb-mediated transcriptional repression (PRC1 complex)
H2BK120ub: Required for H3K4 and H3K79 methylation; facilitates transcription
Altered in [Huntington's disease](/diseases/huntingtons) due to mutant [huntingtin](/proteins/huntingtin) interactions with the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system)

Histone Modifications in Alzheimer's Disease

Global Epigenomic Changes

Large-scale chromatin profiling studies have revealed widespread histone modification changes in AD brains:

H3K27ac redistribution: Nativio et al. (2020) performed genome-wide H3K27ac profiling in AD brains and found massive redistribution rather than simple loss - enhancers at immune/inflammatory genes gain acetylation while neuronal/synaptic gene enhancers lose acetylation ([Nativio et al., 2020](https://doi.org/10.1038/s41593-020-00719-w))
H3K9ac loss: Global decrease in H3K9 acetylation at promoters of synaptic plasticity and memory genes
H4K16ac reduction: Associated with chromatin compaction and gene silencing in AD
H3K4me3 changes: Altered at promoters of tau]-related and inflammatory genes

Mechanisms Driving Epigenetic Dysregulation

HDAC upregulation: Several HDACs (HDAC2, HDAC3, HDAC6) are elevated in AD brains

HAT loss: CBP/p300 activity decreases with [amyloid-beta](/proteins/amyloid-beta) and tau] pathology

Oxidative modification: [reactive oxygen species](/mechanisms/oxidative-stress) directly modify histones and epigenetic enzymes

[Tau](/proteins/tau)-mediated heterochromatin loss: Tau interacts with heterochromatin and its loss leads to aberrant gene expression, including retrotransposon activation

Inflammatory signaling: [NF-κB](/entities/nf-kb) activation recruits HATs to inflammatory gene promoters while HDACs are redirected from neuronal genes

Specific HDAC Roles in AD

HDAC2: Upregulated in AD hippocampal [neurons](/entities/neurons); negatively regulates memory gene expression; its knockdown restores synaptic plasticity and memory in AD mice ([Graff et al., 2012](https://doi.org/10.1038/nature10860))
HDAC3: Negative regulator of memory consolidation; elevated in AD
HDAC6: Deacetylates tau] and alpha-tubulin; promotes tau aggregation; inhibition reduces tau pathology
SIRT1 (Class III [HDAC: Neuroprotective; decreases in AD brains; activates alpha

Histone Modifications in Other Neurodegenerative Diseases

Parkinson's Disease

[alpha-synuclein](/proteins/alpha-synuclein) directly binds histones and inhibits histone acetylation
Nuclear [alpha-synuclein](/proteins/alpha-synuclein) sequesters HATs, reducing global acetylation
HDAC inhibitors protect [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) in MPTP and [alpha-synuclein](/proteins/alpha-synuclein) PD models
H3K27me3 changes at PD risk gene loci (SNCA, [LRRK2](/entities/lrrk2), GBA)

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin) sequesters CBP/p300 (HAT) in aggregates, causing global hypoacetylation
[HDAC](/entities/hdac-enzymes) inhibitors (SAHA, sodium butyrate) improve motor and cognitive phenotypes in HD mice
H3K4me3 is reduced at neuronal identity genes in HD [striatum](/brain-regions/striatum)
HD is the neurodegenerative disease with the strongest evidence for epigenetic therapies

ALS

[TDP-43](/proteins/tdp-43) and [FUS](/entities/fus) interact with histone-modifying complexes
Increased H2AX phosphorylation (gamma-H2AX) indicates DNA damage in [motor neurons](/cell-types/motor-neurons)
HDAC6 inhibition improves axonal transport and motor function in ALS models
[C9orf72](/genes/c9orf72) repeat expansions alter chromatin structure at the repeat locus

Therapeutic Targeting

HDAC Inhibitors

HDAC inhibitors are the most advanced epigenetic therapeutic strategy for neurodegeneration:

| Compound | HDAC Selectivity | Status | Key Evidence |
|----------|-----------------|--------|-------------|
| Vorinostat (SAHA) | Pan-HDAC (I, II) | FDA-approved (cancer) | Improves memory in AD mice; restores histone acetylation |
| Sodium valproate | Class I/IIa | FDA-approved (epilepsy) | Clinical trials in AD; mixed results |
| CI-994 (Tacedinaline) | Class I selective | Preclinical (AD) | Restores hippocampal memory gene expression |
| Tubastatin A | HDAC6 selective | Preclinical | Reduces tau phosphorylation and aggregation |
| RGFP966 | HDAC3 selective | Preclinical | Enhances memory consolidation |
| Compound 3 | HDAC11 selective | Preclinical (2025) | Brain-penetrant; colocalizes with amyloid plaques |

Challenges for Epigenetic Therapies

Selectivity: Pan-HDAC inhibitors affect thousands of genes; isoform-selective inhibitors are preferred
Cell-type specificity: Different cell types require different epigenetic programs; systemic HDAC inhibition may be harmful
[BBB](/entities/blood-brain-barrier) penetration: Many HDAC inhibitors have poor [blood-brain barrier](/entities/blood-brain-barrier) permeability
Side effects: Hematological toxicity, GI effects, fatigue
Dosing: Therapeutic window between efficacy and toxicity is narrow
Irreversibility concerns: Some epigenetic changes may be difficult to reverse once established

Emerging Approaches

BET bromodomain inhibitors: Block readers of acetylated histones; reduce inflammatory gene expression
EZH2 inhibitors: Target H3K27me3 writer; may reactivate silenced neuroprotective genes
LSD1 inhibitors: Block histone demethylase; restore H3K4me at memory genes
CRISPR-based epigenetic editing: Targeted modification of histone marks at specific genomic loci (experimental)
Dual-target inhibitors: Compounds targeting both RIPK1 and HDACs for combined anti-inflammatory and epigenetic effects (2024-2025 development)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
[ENCODE Project](https://www.encodeproject.org/) — Encyclopedia of DNA Elements
[Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data

Brain Atlas Resources

Allen Human Brain Atlas: [Histone Modifications expression search](https://human.brain-map.org/microarray/search/show?search_term=Histone+Modifications)
Allen Mouse Brain Atlas: [Histone Modifications search](https://mouse.brain-map.org/search/index.html?query=Histone+Modifications)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
BrainSpan Developmental Transcriptome: [Histone Modifications developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Histone+Modifications)

Background

The study of Histone Modifications has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Nativio R, et al., An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer's Disease. Nat Genet. 2020;52(10):1024-1035. [DOI (2020)](https://doi.org/10.1038/s41588-020-0696-0)

[Graff J, et al., An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483(7388):222-226. [DOI (2012)](https://doi.org/10.1038/nature10860)

[Unknown, Shukla S, Singh SS. Restoring the epigenome in Alzheimer's Disease: advancing HDAC inhibitors as therapeutic agents. Drug Discov Today. 2024;29(8):104056. [PMID:38830501 (2024)](https://pubmed.ncbi.nlm.nih.gov/38830501/)

[Guan JS, et al., HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243):55-60. [DOI (2009)](https://doi.org/10.1038/nature07925)

[Peleg S, et al., Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 2010;328(5979):753-756. [DOI (2010)](https://doi.org/10.1126/science.1186088)

[Unknown, Konsoula Z, Bhatt AB. Epigenetics in neurodegenerative diseases. Biomolecules. 2024;16(1):103. [DOI (2024)](https://doi.org/10.3390/biom16010103)

[Zheng Y, et al., The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther. 2022;7(1):217. [DOI (2022)](https://doi.org/10.1038/s41392-022-01078-9)

[Unknown, Stilling RM, Fischer A. The role of histone acetylation in age-associated memory impairment and Alzheimer's Disease. Neurobiol Learn Mem. 2011;96(1):19-26. [DOI (2011)](https://doi.org/10.1016/j.nlm.2011.04.002)

[Fischer A, et al., Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447(7141):178-182. [DOI (2007)](https://doi.org/10.1038/nature05772)

[Chuang DM, et al., Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11):591-601. [DOI (2009)](https://doi.org/10.1016/j.tins.2009.06.002)

[Frost B, et al., Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014;17(3):357-366. [DOI (2014)](https://doi.org/10.1038/nn.3639)

[Cook C, et al., Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet. 2014;23(1):104-116. [DOI (2014)](https://doi.org/10.1093/hmg/ddt402)

Pathway Diagram

The following diagram shows the key molecular relationships involving Histone Modifications discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

entities-histone-modifications

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-histone-modifications
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-15e979cbc8ee
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-histone-modifications'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Histone Modifications

Introduction

Overview

Histone Biology

Nucleosome Structure

Introduction

Overview

Histone Biology

Nucleosome Structure

The Histone Code

Major Types of Histone Modifications

Acetylation

Methylation

Phosphorylation

Ubiquitination

Histone Modifications in Alzheimer's Disease

Global Epigenomic Changes

Mechanisms Driving Epigenetic Dysregulation

Specific HDAC Roles in AD

Histone Modifications in Other Neurodegenerative Diseases

Parkinson's Disease

Huntington's Disease

ALS

Therapeutic Targeting

HDAC Inhibitors

Challenges for Epigenetic Therapies

Emerging Approaches

External Links

Brain Atlas Resources

See Also

Background

References

Pathway Diagram

💬 Discussion